Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2021-04-14 Declaration of Voting R…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership thresholds, specifically noting the acquisition/disposal of shares with voting rights by T. Rowe Price Group, Inc. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds. Although the header mentions 'Voting Rights Announcements', the content structure (reporting percentage changes, ISINs, and shareholder details) aligns perfectly with the MRQ category, which is a specific type of major holding disclosure.
2021-04-14 English
Annual financial report 2020
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2020' and contains a comprehensive table of contents covering shareholder letters, management reports, consolidated financial statements (IFRS), and an independent auditor's report. It is a full-length annual report rather than an announcement or a summary, fitting the definition of a 10-K (or equivalent annual report for a non-US entity). FY 2020
2021-04-14 English
Evotec launches 'beLAB2122', translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb
Legal Proceedings Report Classification · 99% confidence The document is a press release dated April 13, 2021, announcing the launch of 'beLAB2122', a translational collaboration between Evotec and Bristol Myers Squibb, involving several German academic institutions. It details a new business/research initiative rather than reporting periodic financial results (like 10-K or IR), management changes (MANG), or shareholder votes (DVA). It is a general corporate announcement concerning strategic partnership and innovation, which does not fit neatly into the specific financial reporting categories (10-K, IR, ER, etc.). Since it is a general corporate news release disseminated via DGAP (a service often used for regulatory announcements), and it doesn't fit the specific definitions for M&A (TAR), Capital Change (CAP/SHA), or Director's Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS), as it is a general, non-financial-specific corporate update.
2021-04-13 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Acquisition/disposal of shares with voting rights' and 'instruments' held by T. Rowe Price International Funds, Inc. in Evotec SE, crossing specific percentage thresholds (3.10% direct voting rights). This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds. Although the header mentions 'Voting Rights Announcements', the content is a specific regulatory filing about shareholding changes, making MRQ the most precise fit over DVA (which is for voting results) or DIRS (which is for director trades).
2021-04-09 English
Evotec and Exscientia announce start of human clinical trials of novel immuno-oncology drug
Regulatory Filings Classification · 100% confidence The document is a news release dated April 9, 2021, announcing that a novel immuno-oncology drug candidate, arising from a joint venture between Evotec and Exscientia, has entered human clinical trials. It details the scientific background, partnership structure, and quotes management. This type of announcement, focusing on operational progress (drug development milestones) rather than periodic financial results (like 10-K or ER) or mandatory regulatory filings (like DIRS or DEF 14A), is best classified as a general corporate announcement. Since it is not a specific financial report, management change, or capital event, and it is disseminated via a news service (DGAP), it fits best under the general 'Regulatory Filings' or 'Miscellaneous' category. Given the options, 'RNS' (Regulatory Filings/General Regulatory Announcements) is the most appropriate fallback for a significant corporate operational update that isn't covered by the more specific codes.
2021-04-09 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Evotec SE: Release according to Article 41 of the WpHG' and specifically announces the 'Publication of total number of voting rights' as of March 31, 2021. It details a 'Type of capital measure' related to a 'Conditional capital increase' and states the 'New total number of voting rights'. This content directly relates to changes in the company's capital structure and the resulting voting power, which aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it mentions voting rights, it is about the total number resulting from a capital action, not the results of a shareholder vote (DVA). Given the focus on capital structure change, SHA is the most appropriate classification.
2021-03-31 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.